These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24832022)

  • 61. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study.
    Sipahi OR; Mermer S; Demirdal T; Ulu AC; Fillatre P; Ozcem SB; Kaya Ş; Şener A; Bulut C; Tekin R; Kahraman H; Özgiray E; Yurtseven T; Sipahi H; Arda B; Pullukçu H; Taşbakan M; Yamazhan T; Aydemir S; Ulusoy S
    Clin Neurol Neurosurg; 2018 Sep; 172():31-38. PubMed ID: 29960893
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii.
    Bian X; Liu X; Feng M; Bergen PJ; Li J; Chen Y; Zheng H; Song S; Zhang J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106271. PubMed ID: 33352235
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 64. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea.
    Seok H; Choi WS; Lee S; Moon C; Park DW; Song JY; Cheong HJ; Kim J; Kim JY; Park MN; Kim YR; Lee HJ; Kim B; Pai H; Jo YM; Kim JH; Sohn JW
    J Glob Antimicrob Resist; 2021 Mar; 24():429-439. PubMed ID: 33571708
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).
    Henwood CJ; Gatward T; Warner M; James D; Stockdale MW; Spence RP; Towner KJ; Livermore DM; Woodford N
    J Antimicrob Chemother; 2002 Mar; 49(3):479-87. PubMed ID: 11864948
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
    Principe L; Capone A; Mazzarelli A; D'Arezzo S; Bordi E; Di Caro A; Petrosillo N
    Microb Drug Resist; 2013 Oct; 19(5):407-14. PubMed ID: 23659601
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.
    Shields RK; Clancy CJ; Gillis LM; Kwak EJ; Silveira FP; Massih RC; Eschenauer GA; Potoski BA; Nguyen MH
    PLoS One; 2012; 7(12):e52349. PubMed ID: 23285002
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Sirijatuphat R; Thamlikitkul V
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5598-601. PubMed ID: 24982065
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Saballs M; Pujol M; Tubau F; Peña C; Montero A; Domínguez MA; Gudiol F; Ariza J
    J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens.
    Jean SS; Hsueh PR
    Expert Opin Pharmacother; 2011 Oct; 12(14):2145-8. PubMed ID: 21895553
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis.
    Mei H; Yang T; Wang J; Wang R; Cai Y
    J Antimicrob Chemother; 2019 Dec; 74(12):3423-3431. PubMed ID: 31377765
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore.
    Lim TP; Tan TY; Lee W; Sasikala S; Tan TT; Hsu LY; Kwa AL
    J Antibiot (Tokyo); 2009 Dec; 62(12):675-9. PubMed ID: 19876075
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
    Qureshi ZA; Hittle LE; O'Hara JA; Rivera JI; Syed A; Shields RK; Pasculle AW; Ernst RK; Doi Y
    Clin Infect Dis; 2015 May; 60(9):1295-303. PubMed ID: 25632010
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical Presentations and Outcomes of Post-Operative Central Nervous System Infection Caused by Multi-Drug-Resistant/Extensively Drug-Resistant
    Liang W; Yuan-Run Z; Min Y
    Surg Infect (Larchmt); 2019 Sep; 20(6):460-464. PubMed ID: 30942663
    [No Abstract]   [Full Text] [Related]  

  • 75. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections.
    Lim SK; Lee SO; Choi SH; Choi JP; Kim SH; Jeong JY; Choi SH; Woo JH; Kim YS
    J Korean Med Sci; 2011 Mar; 26(3):325-31. PubMed ID: 21394298
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
    Betrosian AP; Frantzeskaki F; Xanthaki A; Douzinas EE
    J Infect; 2008 Jun; 56(6):432-6. PubMed ID: 18501431
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
    Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Borraz C; Gudiol F
    J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
    Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
    J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.